CLINICAL TRIAL

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2019-12-30
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Johns Hopkins University

Watch author

Derived topics and classifications

psilocybin Brain Imaging Pharmacology Aging Wellbeing Spirituality Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09 Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced MeditatorsClinicalTrials.gov · 2023-09-21 Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14 Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23 A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy VolunteersClinicalTrials.gov · 2026-02-13 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 Characterization of Altered Waking States of Consciousness in Healthy HumansClinicalTrials.gov · 2021-04-29